{
  "id": "6415c7fb690f196b51000016",
  "type": "factoid",
  "question": "When was Keytruda approved for the treatment of melanoma?",
  "ideal_answer": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA) for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28235882"
  ],
  "snippets": [
    {
      "text": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "September 4, 2014"
}